Phase 3 N=4 Treating Bacterial Overgrowth in Parkinson's Disease
Parkinson's Disease · Small Intestinal Bacterial Overgrowth
Primary: Change in "Off" Time as Measured by Patient Diary — -1.4; -2.8; -0.9; -2.0 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 7; 12; 0; 0 Participants
N/A N=10 KNA Proof-of-Concept
Adherence, Treatment · Retention · Cognitive Impairment, Mild
Primary: Ketogenic Adherence — 8 Participants
Phase 4 N=60 Efficacy of Trypsin-Chymotrypsin On Post-operative Pain After Single Visit Root Canal Treatment
Effect of Drug
Primary: Effect of Trypsin-Chymotrypsin on Post-operative Pain After Single Endodontic Treatment in Teeth With Symptomatic Irreversible Pulpitis — 3.47; 3.53; 2.93; 6.13 score on…
N/A N=1,342 International Registry for Ambulatory Blood Pressure and Arterial Stiffness Telemonitoring
Hypertension
Primary: 24-hour Pulse Wave Velocity (PWV) — 10.6 m/s
N/A N=10 Coronal Mode Ultrasound Guided Hemodialysis Cannulation: Comparison With Standard Cannulation Technique
Arteriovenous Fistula, Cannulation
Primary: Infiltration Due to Dialysis Access Cannulation — 5; 7 infiltration events
Phase 3 N=615 A Study of MD-120 in Patients With Depression
Major Depressive Disorder
Primary: Changes in Total MADRS Score From the Baseline to Week 8 Visit During the Treatment Period — -10.4; -11.1; -11.9 Score on a scale — p=0.509
N/A N=60 Brain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART)
Mood Disorders
Primary: Functional Magnetic Resonance Imaging (fMRI) Blood Oxygen-level Dependent (BOLD) Signal Changes in Left Amygdala at Baseline and at the End of the Intervention — 1.62…
N/A N=40 Daily Activity Study of Health: Increasing Physical Activity in Aging
Aging
Primary: Change in Sedentary Behavior (Average Hour/Day) — -0.11; 0.05 Change in average daily hours — p=0.8
Phase 2 N=161 Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy
Urinary Retention Postoperative
Primary: Time to Spontaneous Void — 1.63; 1.42 hours
N/A N=70 An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
Evaluate Ketogenic Stress
Primary: Change in Beta-hydroxybutyrate Levels in Blood — -0.23; 0.63; 0.24; 0.31 mM
N/A N=10 Histopathological Evaluation of the Periodontal Ligament Subjected to Laser Ablation.
Pulp Necroses
Primary: Cell Count of Inflammatory Infiltrate Per Cross-Sectional Area at 400X Magnification — 10.3; 10.5 Cells / 0.1 mm^2
Phase 3 N=189 Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
Amyotrophic Lateral Sclerosis (ALS)
Primary: The Proportion of NurOwn® Treated Participants With a ≥1.25 Points/Month Improvement in Post-treatment Slope vs. Pre-treatment Slope in ALSFRS-R Score at 28 Weeks…
Phase 2 N=110 Improving Cognitive Health in COVID-19 Survivors
Cognitive Dysfunction · Covid19
Primary: Change in Cognitive Function, as Measured by Number Correct on the Digit Symbol Matching Task — 63.0; 63.5; 67.8; 69.0 number of correct matches — p=0.54
N/A N=43 Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
Type 1 Diabetes
Primary: Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin — 0.08; 0.25; 0.21 mM